Vandana Singh
·
July 11, 2025
Benzinga
FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.
read more
September 17, 2025
September 5, 2025
July 31, 2025
Barchart
July 14, 2025
Financial Times
August 25, 2025